• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿纤维蛋白原β链与酪氨酸磷酸化蛋白联合检测膀胱癌

Combination of urinary fibrinogen β-chain and tyrosine-phosphorylated proteins for the detection of bladder cancer.

作者信息

Giribaldi Giuliana, Filippini Claudia, Viberti Clara, Khadjavi Amina, Finesso Nicole, Ulliers Daniela, Turini Stefano, Bressan Bruno Emilio, Pecoraro Francesca, Prato Mauro, Allione Alessandra, Bellis Matteo De, Montefusco Gabriele, Bonomessi Giulia, Allasia Marco, Matullo Giuseppe, Soria Francesco, Gontero Paolo

机构信息

Department of Oncology, University of Turin, Turin, Italy.

Department of Surgical Sciences, University of Turin, Turin, Italy.

出版信息

Future Sci OA. 2021 Oct 11;7(9):FSO758. doi: 10.2144/fsoa-2021-0060. eCollection 2021 Oct.

DOI:10.2144/fsoa-2021-0060
PMID:34737890
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8558871/
Abstract

AIM

To evaluate the performance of urinary fibrinogen β-chain (FBC) - either alone or associated with urinary tyrosine-phosphorylated proteins (UPY) - as bladder cancer (BCa) diagnostic biomarker.

MATERIALS & METHODS: 164 subjects were tested.

RESULTS

Significantly different FBC and UPY levels were found between BCa patients and controls, as well as between low-grade and high-grade cancers. The diagnostic accuracy was 0.84 for FBC and 0.87 for UPY. The combination of FBC and UPY improved the accuracy to 0.91. The addition of clinical variables (age, gender, and smoking habit) to FBC and UPY into a model for BCa prediction significantly improved the accuracy to 0.99. The combination of FBC and UPY adjusted for clinical variables associates with the highest sensitivity and good specificity.

CONCLUSION

Urinary FBC and UPY could be used as biomarkers for BCa diagnosis.

摘要

目的

评估尿纤维蛋白原β链(FBC)单独或与尿酪氨酸磷酸化蛋白(UPY)联合作为膀胱癌(BCa)诊断生物标志物的性能。

材料与方法

对164名受试者进行了检测。

结果

BCa患者与对照组之间以及低级别和高级别癌症之间的FBC和UPY水平存在显著差异。FBC的诊断准确率为0.84,UPY为0.87。FBC和UPY联合使用可将准确率提高到0.91。将临床变量(年龄、性别和吸烟习惯)添加到FBC和UPY中用于BCa预测模型,可显著提高准确率至0.99。针对临床变量进行调整后的FBC和UPY联合使用具有最高的敏感性和良好的特异性。

结论

尿FBC和UPY可作为BCa诊断的生物标志物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81a1/8558871/127b78177dca/fsoa-07-758-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81a1/8558871/775cde4a3297/fsoa-07-758-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81a1/8558871/6db2f8412e92/fsoa-07-758-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81a1/8558871/127b78177dca/fsoa-07-758-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81a1/8558871/775cde4a3297/fsoa-07-758-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81a1/8558871/6db2f8412e92/fsoa-07-758-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/81a1/8558871/127b78177dca/fsoa-07-758-g3.jpg

相似文献

1
Combination of urinary fibrinogen β-chain and tyrosine-phosphorylated proteins for the detection of bladder cancer.尿纤维蛋白原β链与酪氨酸磷酸化蛋白联合检测膀胱癌
Future Sci OA. 2021 Oct 11;7(9):FSO758. doi: 10.2144/fsoa-2021-0060. eCollection 2021 Oct.
2
Early diagnosis of bladder cancer through the detection of urinary tyrosine-phosphorylated proteins.通过检测尿液中酪氨酸磷酸化蛋白实现膀胱癌的早期诊断。
Br J Cancer. 2015 Jul 28;113(3):469-75. doi: 10.1038/bjc.2015.232. Epub 2015 Jun 30.
3
Detection of Urothelial Bladder Cancer Based on Urine and Tissue Telomerase Activity Measured by Novel RT-TRAP-2PCR Method.基于新型逆转录-端粒重复扩增-2聚合酶链反应法检测尿液和组织端粒酶活性诊断尿路上皮膀胱癌
J Clin Med. 2021 Mar 4;10(5):1055. doi: 10.3390/jcm10051055.
4
HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.HOXA9、PCDH17、POU4F2 和 ONECUT2 作为血尿中国患者膀胱癌检测的尿液生物标志物组合。
Eur Urol Focus. 2020 Mar 15;6(2):284-291. doi: 10.1016/j.euf.2018.09.016. Epub 2018 Oct 9.
5
Bladder cancer risk stratification using a urinary mRNA biomarker panel - A path towards cystoscopy triaging.基于尿液 mRNA 生物标志物panel 的膀胱癌风险分层——一种用于膀胱镜分诊的策略。
Urol Oncol. 2021 Aug;39(8):497.e9-497.e15. doi: 10.1016/j.urolonc.2021.02.011. Epub 2021 Mar 22.
6
Urinary APE1/Ref-1: A Potential Bladder Cancer Biomarker.尿液APE1/Ref-1:一种潜在的膀胱癌生物标志物。
Dis Markers. 2016;2016:7276502. doi: 10.1155/2016/7276502. Epub 2016 Jan 21.
7
Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.用于尿液样本中膀胱癌无创检测的AIB1和EIF5A2的鉴定与验证
Oncotarget. 2016 Jul 5;7(27):41703-41714. doi: 10.18632/oncotarget.9406.
8
Urinary levels of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein as a diagnostic biomarker in patients with bladder cancer.肝癌-肠-胰腺/胰腺炎相关蛋白在膀胱癌患者中的尿液水平作为诊断生物标志物。
BMC Urol. 2012 Sep 4;12:24. doi: 10.1186/1471-2490-12-24.
9
Bladder diary measurements in asymptomatic females: functional bladder capacity, frequency, and 24-hr volume.无症状女性的膀胱日记测量:功能性膀胱容量、排尿频率和24小时尿量。
Neurourol Urodyn. 2007;26(3):341-9. doi: 10.1002/nau.20241.
10
Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.尿代谢物变化的研究及其在膀胱癌生物标志物发现中的应用。
Int J Cancer. 2018 Jul 15;143(2):408-418. doi: 10.1002/ijc.31323. Epub 2018 Mar 2.

引用本文的文献

1
The intratumoral microbiota heterogenicity is related to the prognosis and tumorigenesis of cervical cancer.肿瘤内微生物群的异质性与宫颈癌的预后和肿瘤发生有关。
Front Cell Infect Microbiol. 2025 May 13;15:1574511. doi: 10.3389/fcimb.2025.1574511. eCollection 2025.

本文引用的文献

1
Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer.全身综合炎症评分(SCIS):一种预测高危非肌层浸润性尿路上皮膀胱癌患者肿瘤学结局的新评分。
Transl Androl Urol. 2021 Feb;10(2):626-635. doi: 10.21037/tau-20-1272.
2
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.欧洲泌尿外科学会非肌肉浸润性膀胱癌(TaT1 和原位癌)指南 - 2019 年更新版。
Eur Urol. 2019 Nov;76(5):639-657. doi: 10.1016/j.eururo.2019.08.016. Epub 2019 Aug 20.
3
Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor.
绝对嗜碱性粒细胞计数与接受经尿道膀胱肿瘤切除术 (TURBT) 后卡介苗灌注治疗的高级别 T1 膀胱癌患者复发时间相关。
World J Urol. 2020 Jan;38(1):143-150. doi: 10.1007/s00345-019-02754-2. Epub 2019 Apr 16.
4
Molecular markers in bladder cancer.膀胱癌的分子标志物。
World J Urol. 2019 Jan;37(1):31-40. doi: 10.1007/s00345-018-2503-4. Epub 2018 Sep 26.
5
MMP23B expression and protein levels in blood and urine are associated with bladder cancer.MMP23B 在血液和尿液中的表达和蛋白水平与膀胱癌相关。
Carcinogenesis. 2018 Oct 8;39(10):1254-1263. doi: 10.1093/carcin/bgy098.
6
An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.体重指数增加与 T1 期膀胱癌患者接受卡介苗免疫治疗的预后较差相关。
World J Urol. 2019 Mar;37(3):507-514. doi: 10.1007/s00345-018-2397-1. Epub 2018 Jul 10.
7
An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer.用于非肌肉浸润性膀胱癌监测的现有尿生物标志物的最新目录。
World J Urol. 2018 Dec;36(12):1981-1995. doi: 10.1007/s00345-018-2380-x. Epub 2018 Jun 21.
8
Role of the Coagulation System in Genitourinary Cancers: Review.凝血系统在泌尿生殖系统癌症中的作用:综述
Clin Genitourin Cancer. 2017 Jul 26. doi: 10.1016/j.clgc.2017.07.013.
9
Role of coagulation factors in urological malignancy: A prospective, controlled study on prostate, renal and bladder cancer.凝血因子在泌尿系统恶性肿瘤中的作用:一项关于前列腺癌、肾癌和膀胱癌的前瞻性对照研究。
Int J Urol. 2017 Feb;24(2):130-136. doi: 10.1111/iju.13271. Epub 2016 Dec 22.
10
Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter Study.一项多中心研究中用于监测复发性尿路上皮癌的多基因尿液生物标志物检测的性能特征
J Urol. 2017 Jun;197(6):1419-1426. doi: 10.1016/j.juro.2016.12.010. Epub 2016 Dec 14.